UID:
almahu_9949708066202882
Format:
1 online resource (367 pages)
Edition:
1st ed.
ISBN:
9783031335334
Note:
Intro -- Contents -- 1: Rise of the Theranostics Empire: A Commentary on Dr. Baum's Achievements -- 1.1 The Beginning -- 1.2 The Impedance -- 1.3 The Fertilization -- 1.4 Hard Yards -- 1.5 Expansion of the Empire -- 1.6 New Capital -- 2: Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment -- 2.1 Introduction -- 2.2 Patterns of Response -- 2.2.1 Pseudoprogression -- 2.2.2 Hyperprogression -- 2.2.3 Durable Response -- 2.3 Mechanism -- 2.4 18FPET CT and irAE -- 2.4.1 Therapy-Related Inflammation and Inverse Relation Liver SUV/Spleen SUV [18] -- 2.5 Conclusion -- References -- 3: Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours -- 3.1 Introduction -- 3.2 Molecular Imaging of Neuroendocrine Neoplasms -- 3.3 Surgical Treatment -- 3.4 Surgery in Combination with Peptide Receptor Radionuclide Therapy -- 3.5 Conclusions -- References -- 4: From Concept to Clinic and Commercialization: Cowboys Wanted -- 4.1 Professor Richard Baum -- 4.2 The Great Bexxar® Disaster -- 4.3 "Us Versus Them" -- 4.4 Intellectual Property: Who Cares? -- 4.5 Imaging Is Not an Easy Business -- 4.6 Entrepreneurs Beware -- 4.7 Build It and They Will Come -- 4.8 A Fragile Supply Chain -- 4.9 Future Frontiers -- 4.10 Concluding Remarks -- References -- 5: From Radiochemistry of the Lanthanides to 225Ac and the Interference with Richard Baum -- 5.1 Personal Introduction -- 5.2 Situation of Nuclear Medicine in the 60-th -- 5.3 How to Make Sort-lived Nuclides Far from Beta Stability -- 5.4 Optimized Extraction Chromatography -- 5.5 Separations Based on Szilard-Chalmers Effect -- 5.6 High-temperature Release Studies of Radio-lanthanides from Refractory Metals -- 5.7 ISOLDE and the On-line Production Lanthanide Nuclides.
,
5.8 Isotopes in Medicine: Situation in the 60-th -- 5.9 Metallic Positron Emitters -- 5.10 The Alpha Emitters 149Tb and 225Ac -- 5.11 From "Radioactive Ion Beams for Bio-Medical Research" Until CERN Medicis: A New Facility -- 5.12 The 225Ac Story -- 5.13 Where the 225Ac Comes From -- 5.14 Summarizing -- References -- 6: "How Do You Feel About Dosimetry?" The Gretchenfrage of Radionuclide Therapy -- 6.1 The Gretchenfrage -- 6.2 The Forms of Dosimetry in a Nutshell -- 6.3 Dose Quantities and Dose-Response in EBRT -- 6.4 Dose-Response I: Radiotoxicities in Radionuclide Therapy -- 6.5 Dose-Response II: Tumor Response in Radionuclide Therapy -- 6.6 The Answer to the Gretchenfrage -- References -- 7: The LuGenIum Triptych: Ode to a Theranostic Transcriptome -- 7.1 Retrospective Analysis of Toxicity -- 7.2 Circulating NET Transcripts -- 7.3 Circulating NET Transcripts and SSR Imaging -- 7.4 Circulating NET Transcripts and PRRT -- 7.5 Validation Study of PRRT Genomic Signature in Blood (PPQ) for the Prediction of 177Lu-octreotate Efficacy -- 7.6 Validation Study of Multigene NET-Specific Circulating Transcript Signature for the Monitoring of 177Lu-octreotate Efficacy -- 7.7 Future Developments -- References -- 8: A Tree Can Be Recognized by Its Fruit -- 8.1 Introduction -- 8.2 Fruits of Scientist Baum -- 8.3 Fruits of Doctor Baum -- 8.3.1 Fruits of Our Friend Baum -- References -- 9: IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle-Income Countries -- 9.1 Introduction -- 9.2 Key Challenges -- 9.3 Interventions -- 9.4 Results -- 9.4.1 Technical Cooperation Programme -- 9.4.2 Quality Assurance -- 9.4.3 Procurement -- 9.4.4 Education -- 9.4.5 Coordinated Research Activities -- 9.5 Conclusion -- References -- 10: Radionuclide Therapy in Brain Tumours -- 10.1 Introduction.
,
10.1.1 Radionuclides Used in the Therapy -- 10.1.1.1 Alpha-Emitter Radionuclide -- 10.1.1.2 Beta-Emitter Radionuclide -- 10.1.2 Routes of Drug Administration -- 10.1.2.1 Systemic Administration of Radioconjugates -- 10.1.2.2 Locoregional Application of Radioconjugates -- 10.2 Peptide Receptor Radionuclide Therapy -- 10.2.1 Biologic Targets for PRRT -- 10.2.1.1 Neurokinin Type 1 Receptor -- 10.2.1.2 Glioma Chloride Channels -- 10.2.1.3 Somatostatin Receptor -- 10.2.2 Clinical Studies -- 10.3 Immune-Based Radionuclide Therapy -- 10.3.1 Biologic Targets for RIT -- 10.3.1.1 Tenascin-C -- 10.3.1.2 Epidermal Growth Factor Receptor -- 10.3.1.3 Neural Cell Adhesion Molecule -- 10.3.1.4 Histone H1 -- 10.3.2 Future Novel Targets -- 10.3.2.1 Fibulin-3 -- 10.3.3 Clinical Studies -- 10.3.4 Challenges and Future Directions -- 10.3.4.1 Challenges -- 10.3.4.2 The Blood-Brain Barrier (BBB) -- 10.3.4.3 Tumoral Heterogeneity -- 10.3.5 Conclusion -- References -- 11: Modern Diagnostic and Therapeutic Approaches in Thyroid Diseases: Theranostics and the Changing Role of Radioactive Isotopes -- 11.1 Conclusion -- References -- 12: Cardiotoxicity of Targeted Therapies: Imaging of Heart Does Matter -- 12.1 Cancer Targeted Therapies -- 12.2 Cardiotoxicity of Cancer Targeted Therapy -- 12.3 Diagnostic Tools to Detect Myocardial Toxicity -- 12.3.1 Anamnesis and Risk Stratification -- 12.3.2 Electrocardiography -- 12.3.3 Cardiac Biomarkers -- 12.3.4 Imaging Modalities for Cardiotoxicity Screening -- 12.3.4.1 Echocardiography -- 12.3.4.2 Cardiac Magnetic Resonance -- 12.3.4.3 Nuclear Positron Emission Tomography -- 12.3.4.4 Conventional Nuclear Imaging -- 12.3.4.5 Cardiac Computed Tomography, Angio-Coronary Computer Tomography -- 12.4 Summary -- References.
,
13: The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM -- 13.1 Introduction -- 13.2 No-Carrier-Added Lutetium-177: The Gold Standard for Radionuclide Treatment -- 13.3 No-Carrier-Added Lutetium-177-Edotreotide for Treatment of Neuroendocrine Tumours -- 13.4 Conclusion and Acknowledgements -- References -- 14: Fighting for PET in German Oncological Guidelines and for Its Reimbursement by Statutory Health Insurances -- References -- 15: Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC -- 15.1 Introduction -- 15.2 Prostate-Specific Membrane Antigen as Biological Target -- 15.3 PSMA PET -- 15.4 PSMA β-Particle Radioligand Therapy -- 15.5 PSMA α-Particle Radioligand Therapy -- 15.5.1 Actinium-225 -- 15.5.2 Bismuth-213 -- 15.5.3 Thorium-227 -- 15.5.4 Lead-212 -- 15.5.5 Terbium-149 -- 15.6 Summary -- References -- 16: From Radioimmunodetection to Radiomolecular Precision Oncology Via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles -- References -- 17: Nuclear Medicine and Surgery on the Way to Personalized Medicine. Ten Years of Clinical and Translational Oncology and Research -- References -- 18: PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer -- References -- 19: The Role of Individuals for Innovation: The Nuclear Medicine Biotope -- References -- 20: Working at Isotopentherapiestation D3: A Daily Challenge or Adventure Never Stops -- 21: Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration -- References -- 22: Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation -- 22.1 Introduction.
,
22.2 Peptides and GPCR Targets on Tumors -- 22.3 Radiometals and Their Chelators in Cancer Theranostics -- 22.4 Metabolic Stability of Radiopeptides: The Pep-Protect Concept -- 22.5 Radiopeptide Agonists and Antagonists -- 22.6 Radiopeptide Candidates for Clinical Translation -- References -- 23: Terbium "Sisters": More Than just a "Swiss Army Knife" -- 23.1 Introduction -- 23.2 The PET Sister: Terbium-152 -- 23.3 The SPECT Sister: Terbium-155 -- 23.4 The Alpha Therapy Sister: Terbium-149 -- 23.5 The Beta TherapyPLUS Sister (βτ̔̈ΑΕ·/Conversion/Auger-e)̄: Terbium-161 -- 23.6 Conclusion and Outlook -- References -- 24: High-Performance Radiopharmacy: The Base for Precision Oncology -- References -- 25: Analyzing the Science Footprint of Richard P. Baum -- 25.1 Introduction -- 25.2 Material and Methods -- 25.3 Results -- 25.4 Discussion -- 25.5 Conclusion -- References -- 26: Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA? -- 26.1 Introduction -- 26.2 177Lu-PSMA Versus 225Ac-PSMA PRT in mCRPC -- 26.3 Efficacy of 225Ac-PSMA as a Last-Line Therapy of mCRPC -- 26.4 Toxicities of 225Ac-PSMA for PRLT of mCRPC -- 26.5 Upfront Application of 225Ac-PSMA for Therapy of mCRPC in Chemotherapy-Naïve Patients -- 26.6 Conclusion and Future Perspectives -- References -- 27: Sola Dosis Facit Venenum: Dosimetry for Molecular Radiotherapy in Bad Berka -- 27.1 Introduction -- 27.2 Bad Berka Dose Protocol -- 27.3 Dosimetry in Daily Clinical Routine -- 27.4 Dosimetry for PRRT -- 27.5 PRRT Antagonists -- 27.6 Dosimetry for PSMA Radioligand Therapy -- 27.7 Conclusions -- References -- 28: On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer -- 28.1 Introduction -- 28.2 203Pb SPECT/CT Imaging in Advance of 212Pb α-RT.
,
28.3 Prediction of 212Pb Dosimetry Based on 203Pb Imaging.
Additional Edition:
Print version: Prasad, Vikas Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum Cham : Springer International Publishing AG,c2024 ISBN 9783031335327
Language:
English
Keywords:
Electronic books.
;
Festschrift
;
Festschrift
;
Festschrift
;
Festschrift
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
URL:
Volltext
(kostenfrei)
